Breast cancer

MK-2870-010

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Open at Paris since : 24/10/2024
Target : Adult
Phase : Phase III

Trial description

To compare MK-2870 to TPC;with respect to PFS per RECIST 1.1 as;assessed by BICR in all participants.;Hypothesis (H1): MK-2870 is superior to;TPC with respect to PFS per RECIST 1.1;by BICR in all participants.

Url of the trial

Main investigator

DELPHINE LOIRAT

Médecin

Contact